Diagonal Bio (DIABIO.ST) Stock Analysis & AI Equity Report
Diagonal Bio (DIABIO.ST) overview
Diagonal Bio (DIABIO.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Diagonal Bio reported revenue of SEK 0.1m and operating profit of SEK -9.4m; the year-end share price was 0.02 SEK and market capitalisation was SEK 4.6m. Diagonal Bio is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Diagonal Bio's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-29. Data will be refreshed during report generation.
About Diagonal Bio
Diagonal Bio is a Swedish biotechnology company developing diagnostic platforms for detecting genetic markers in DNA and RNA. Its products include the PANVIRAL platform for pathogen detection and the LAMPlify system for broader, less regulated uses. The company currently focuses on animal health applications, including equine diagnostics and other veterinary markets.
Generate the Diagonal Bio report
Diagonal Bio is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Diagonal Bio and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.